The completion of enrollment is a positive catalyst, but the stock may have already priced in this milestone. Watch for data readouts and PMA submission progress. Approval is not guaranteed; monitor for any delays or negative data.
DRTS drugs
DRTS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $8.51entry
- T+1 · 6mo ago +21.50%α +21.27% · $10.34
- T+5 · 6mo ago +22.33%α +20.86% · $10.41
- T+20 · 5mo ago +9.87%α +9.85% · $9.35
- T+60 · 3mo ago +53.70%α +48.86% · $13.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau completed enrollment in its ReSTART pivotal trial (88 patients) for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, a key step toward FDA PMA approval. The company has Breakthrough Device Designation and submitted the first PMA module in January 2026. This milestone de-risks the regulatory pathway but approval and commercialization remain uncertain.
Key Facts
- Completed enrollment of 88 patients in ReSTART pivotal trial for recurrent cSCC.
- First U.S. pivotal study for Alpha Tau to complete enrollment.
- Alpha DaRT has FDA Breakthrough Device Designation for this indication.
- First module of modular PMA application submitted in January 2026.
- cSCC is the second most common skin cancer with rising incidence and unmet need.
- Trial co-primary endpoints: objective response rate and duration of response at 6 months.
Financial Impact
No financial figures disclosed; potential future revenue from FDA approval in cSCC, but timeline and market size not quantified.
Risk Factors
- FDA may not approve PMA; clinical data may not meet endpoints.
- Competition from existing and emerging therapies for cSCC.
- Company has limited operating history and needs additional funding.
- Stock may have already priced in this milestone; limited upside from here.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291075 |
Track record
25 reports on DRTS
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 11 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers